相信,最近的日本強震海嘯,讓大家重新體認大自然的無情反撲,更讓我們更加珍惜彼此周遭熟悉的人事物,把握現在和當下。
希望大家都能夠繼續不斷的走下去, 永不放棄直到最後, 一起加油!
本網誌設立的目的在於提供MS多發性硬化症的相關醫療資訊,並且以一過來人的身分分享自己發病過程和對抗這個罕見疾病的經驗和心路歷程. 希望我的個人經驗能夠讓同樣遭受這種疾病的人獲得身體上或者是心理上的幫助,而這將是我最大的快樂!! 我更希望這種病不要發生在正常的人身上,希望能夠藉由我的網誌來換醒更多人對於健康的重視!!
按摩緩解便秘的方法
"My fatigue level has improved greatly. I continue to amaze my husband Darren when he gets home from work and I'm still on the go. Unheard of before!!! My sensory or nerve pain has improved greatly. I wonder how I ever lived with it. I feel so much more alert and pulled together. I have been very busy these days. I have been feeling very well since my return home and I have been working very hard on my physiotherapy and am determined to strengthen this leg.
(Dawnia was liberated January 14 - dmcleod@wightman.ca This e-mail address is being protected from spambots. You need JavaScript enabled to view it )
PIERO SCARSELLA (Toronto, Ontario, JAN, 2011)
“I find that my leg strength is a little bit better, I am able to peddle my stationary bicycle longer. My balance is better so that now I can stand up straight, more or less, and keep my balance for a minute or two. My head feels clearer and playing with ideas and numbers is easier. This is good news for me because if all works out as we hope, one day I will go to work and pay taxes, so I will have to become a student again. If everything works out taking courses should be easier for me. Piero can be reached at pieroscarsella@rogers.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
“My head feels more clear.My blood circulation has improved and my hands, legs, and feet actually warm up now!!!I (Contact Diana at diana@dianazimmer.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it or through her website at www.DianaZimmer.com )
最近國外在靜脈擴張手術一些病友的經驗
天氣影響
默克的多發性硬化症藥物Cladribine未獲美國FDA批準,后者要求前者進行更多分析與研究,以便更好地了解藥物的安全風險。
綜合媒體3月2日報導,德國默克制藥公司(Merck KGaA)周三(3月2日)表示,美國食品和藥物管理局(U.S. Food and Drug Administration,FDA)沒有批準其口服多發性硬化症治療藥Cladribine的上市申請。
上述決定令默克公司遭遇挫折,某個歐盟小組在上個月曾經確認了對於Cladribine的否定意見。
默克制藥在聲明中表示,FDA要求其進行更多分析與研究,以便更好地了解藥物的安全風險以及整體利益風險。默克計劃同FDA舉行一次審查總結會議,以便明確下一步的措施,并且探明現有數據是否能夠解決FDA提出的問題。
在歐盟做出決定之后,默克表示,依然承諾繼續并且完成Cladribine的臨床試驗,但多數分析師已經將此項藥品從其評估中移除。
Cladribine為全球首劑多發性硬化症治療藥品,但僅在澳大利亞與俄羅斯這樣的縫隙市場獲批上市。
作為Cladribine的競爭對手,瑞士制藥商諾華公司(Novartis AG)生產的Gilenya已經在美國與俄羅斯獲批上市,并且上個月獲得了歐洲藥物監管機構的肯定意見。
就先等諾華的Gilenya吧
默克的多發性硬化症藥物Cladribine未獲美國FDA批準